Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer

References

• RamalingamSBelaniCSystemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directionsOncologist20081351318263769
   PubMed Web of Science ®Google Scholar
• DempkeaWCMSutobTReckcMTargeted therapies for non-small cell lung cancerLung Cancer20106725727419914732
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAInoueKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• BergerWSetinekUHollausPMultidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implicationsJ Cancer Res Clin Oncol200513135536315856298
   PubMed Web of Science ®Google Scholar
• SinghTRShankarSChenXSynergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/apo-2 ligand on apoptosis and on regression of breast carcinoma in vivoCancer Res2003635390540014500373
   PubMed Web of Science ®Google Scholar
• KruytFAETRAIL and cancer therapyCancer Lett2008263142518329793
   PubMed Web of Science ®Google Scholar
• YouMSavarajNWangpaichitrMThe combination of ADIPEG20 and TRAIL effectively increases cell death in melanoma cell linesBiochem Biophys Res Commun201039476076620227389
   PubMed Web of Science ®Google Scholar
• KelleySKHarrisLAXieDPreclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safetyJ Pharmacol Exp Ther200129313811561060
   PubMed Web of Science ®Google Scholar
• AshkenaziAPaiRCFongSSafety and antitumor activity of recombinant soluble Apo2 ligandJ Clin Invest199910415516210411544
   PubMed Web of Science ®Google Scholar
• StegehuisJHde WiltLHde VriesEGGroenHJde JongSKruytFATRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectivesDrug Resist Updat20101321520036602
   PubMed Web of Science ®Google Scholar
• WangMJLiuSLiuYActinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cellsNeurosci Res200759404617707539
   PubMed Web of Science ®Google Scholar
• MatsuzakiHSchmiedBMUlrichACombination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cellsClin Cancer Res2001740741411234897
   PubMed Web of Science ®Google Scholar
• FanQ-LZouW-YSongL-YSynergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivoCancer Chemother Pharmacol20055518919615290100
   PubMed Web of Science ®Google Scholar
• WalczakHMillerREAriailKTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivoNat Med199951571639930862
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res1994549879928313389
   PubMed Web of Science ®Google Scholar
• GuoLFanLPangZTRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomesJ Control Release20111549310221609741
   PubMed Web of Science ®Google Scholar
• GuoLFanLRenJA novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomesNanotechnology20112226510521586819
   PubMed Web of Science ®Google Scholar
• HiraAWatanabeHMaedaYRole of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cellsBiochem Pharmacol20087597398018054347
   PubMed Web of Science ®Google Scholar
• BradfordMMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem197672248254942051
   PubMed Web of Science ®Google Scholar
• SunSYYuePWuGSMechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cellsOncogene1999182357236510327056
   PubMed Web of Science ®Google Scholar
• KokS-HYehC-CChenM-LEsculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cellsOral Oncol2009451067107219720557
   PubMed Web of Science ®Google Scholar
• HarashimaHKiwadaHLiposomal targeting and drug delivery: kinetic considerationAdv Drug Deliver Rev199619425444
   Web of Science ®Google Scholar
• WuGSTRAIL as a target in anti-cancer therapyCancer Lett200828515
   Web of Science ®Google Scholar
• PanGNiJWeiY-FAn antagonist decoy receptor and a death domain-containing receptor for TRAILScience19972778158189242610
   PubMed Web of Science ®Google Scholar
• SafaARDayTWWuCHCellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapyCurr Cancer Drug Targets20088374618288942
   PubMed Web of Science ®Google Scholar
• EggertAGrotzerMAZuzakTJResistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expressionMed Pediatr Oncol20003560360711107127
   PubMedGoogle Scholar
• KimEHYoonMJKimSUArsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer- binding protein homologous protein–dependent DR5 up-regulationCancer Res20086826627518172319
   PubMed Web of Science ®Google Scholar
• FreseSFrese-SchaperMAndresA-CCardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5Cancer Res2006665867587316740726
   PubMed Web of Science ®Google Scholar
• LiuXYuePZhouZDeath receptor regulation and celecoxib-induced apoptosis in human lung cancer cellsJ Natl Cancer Inst2004961769178015572759
   PubMed Web of Science ®Google Scholar
• NakataSYoshidaTHorinakaMHistone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cellsOncogene2004236261627115208660
   PubMed Web of Science ®Google Scholar
• GuanBYuePLotanREvidence that the human death receptor 4 is regulated by activator protein 1Oncogene2002213121312912082627
   PubMed Web of Science ®Google Scholar
• FreseSPirniaFMiescherDPG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL induced apoptosis requires activation of ERK2Oncogene2003225427543512934102
   PubMed Web of Science ®Google Scholar
• SongJHKandasamyKAsKABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosisJ Biol Chem2008283250032501318599488
   PubMed Web of Science ®Google Scholar
• GuanBYuePClaymanGEvidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated geneJ Cell Physiol20011889810511382926
   PubMed Web of Science ®Google Scholar
• Gómez-BenitoaMMartinez-LorenzobMJAnelaAMembrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAILExp Cell Res20073132378238817462628
   PubMed Web of Science ®Google Scholar
• ZhangYZhangBTRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5Mol Cancer Res200861861187119074831
   PubMed Web of Science ®Google Scholar
• ZauliGPandolfiAGonelliATumor necrosis factor–related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cellsCirc Res20039273274012649264
   PubMed Web of Science ®Google Scholar
• SecchieroPGonelliACarnevaleEEvidence for a proangiogenic activity of TNF-related apoptosis-inducing ligandNeoplasia2004636437315256058
   PubMed Web of Science ®Google Scholar
• IshidaTKiwadaHAccelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomesInt J Pharm2008354566218083313
   PubMed Web of Science ®Google Scholar
• NaganeMPanGWeddleJJIncreased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivoCancer Res20006084785310706092
   PubMed Web of Science ®Google Scholar
• WangSRenWLiuJTRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivoClin Cancer Res2010162591260420406839
   PubMed Web of Science ®Google Scholar
• JinHYangRRossJCooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survivalClin Cancer Res2008147733774019047100
   PubMed Web of Science ®Google Scholar
• DuikerEWMomCHDe JongSThe clinical trail of TRAILEur J Cancer2006422233224016884904
   PubMed Web of Science ®Google Scholar
• WernerABde VriesETaitSWGBcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit its collaboration with pro-apoptotic Bak or BaxJ Biol Chem2002277227812278811929871
   PubMed Web of Science ®Google Scholar